How GHK-Cu is injected, from the record: what clinic pages state about sites and frequency, the human injection evidence (none), the sting, and units per vial.
"Where to inject GHK-Cu" is asked about a copper peptide that has no injectable label, no registered injection trial and no published injection study in people. The answers that rank are clinic blogs, a telehealth provider's guide, forum threads and pages on unrelated domains that repeat each other. This page sets out what each named source states, opened on 2026-10-27, counts the human record, and converts the circulating amounts into syringe units for the 50 mg and 100 mg vials. It describes; it recommends no amount, site or schedule.
The figures themselves are on the GHK-Cu dosage page; the general subcutaneous technique as the labels of approved injected peptides describe it is on how peptides are injected.
What each source states
| Source |
Site(s) |
Amount per injection |
Frequency |
| PeRx telehealth page (updated 2026-08-29) |
Abdomen 2 in. from navel, front/outer thigh, upper outer glute, back of deltoid |
20 units at 10 mg/mL, stated as 2 mg |
Once daily, Monday to Friday; "no cycling break" |
| Range Medical patient guide (undated) |
Not specified beyond "spots with fewer nerves" |
Not stated |
Not stated |
| copperpeptidedirect.com (dated 2026-07-24) |
Abdomen (2-inch ring around the navel avoided), outer thigh, back of upper arm, described as "convention borrowed from other subcutaneous drugs" |
Not stated on the section read |
Not stated |
| Vendor and protocol pages (recorded on this site 2026-09-18) |
Subcutaneous |
1–2 mg (one page up to 3 mg) |
Daily, or five days on and two off, 4 to 12 weeks |
| Any regulator, any trial registry |
— |
— |
Nothing for injected GHK-Cu |
Every row is a provider's or seller's own convention. The only page that comments on where its site list comes from says it is borrowed from other drugs, which is accurate: abdomen, thigh and upper arm are the sites the GLP-1 and tesamorelin labels give for their own products.
The human injection record
Counted on 2026-10-27:
- ClinicalTrials.gov: 4 records name GHK-Cu. NCT07437586 tests a 0.1% topical gel on small wounds (phase 2, recruiting); NCT07706361 measures circulating GHK after a wearable patch (not yet recruiting); NCT07888595 applies a serum of several peptides to the skin at about 1 to 3 mg/mL (early phase 1); NCT05932732 is a completed facial-product study. None injects GHK-Cu.
- PubMed: 2 records tagged as human studies mention GHK-Cu with injection or subcutaneous use. One is a materials paper on bone scaffolds; the other is the 2026 orthopaedic review quoted in the facts above, which names GHK-Cu among the injectable peptides marketed to patients and finds no clinical data for musculoskeletal use.
- Nearest human work: intradermal scalp injections of a multi-ingredient growth-factor formulation containing copper tripeptide-1 in a 1,000-patient series with no control group (Kapoor 2018, PMID 29482481, as recorded on the dosage page), and topical cream after laser resurfacing in 13 patients (2006). Neither gives a milligram dose of GHK-Cu under the skin.
- Animal injection work: the 2015 rat knee study above, given into the joint, not under the skin, with an effect that faded once injections stopped.
So the circulating schedule, the site list and the daily milligram figures trace to no human measurement. The absence is the finding.
The sting
Injected GHK-Cu is widely described as stinging more than other peptides. The explanations offered are the copper itself, a fast push of the plunger and a site near a nerve, all three on the Range Medical guide. None of the pages read cites a measurement, and a PubMed search on 2026-10-27 found no study of injection-site pain with GHK-Cu. What can be stated is the volume: the same milligram is a larger volume at a dilute concentration, as the table below shows.
The vitamin C rule
The two-hour gap between an injection and vitamin C appears on the PeRx page and in Google's AI answer for this search. The page's only citation in that section is a 2020 narrative review on GHK as an anti-ageing peptide, cited for copper binding. The 8 PubMed records that mention GHK with ascorbic acid are laboratory, formulation and cosmetic studies; none tests vitamin C and injected GHK-Cu together in people. The rule is the provider's, reported here as theirs.
The amounts, as syringe units
Units on a U-100 syringe = milligrams ÷ concentration in mg/mL × 100; one unit is 0.01 mL. GHK-Cu vials are 50 mg and 100 mg, the sizes this site's calculator uses; the PeRx vial is supplied already in solution at 10 mg/mL.
| Vial + water |
Concentration |
1 mg |
2 mg |
3 mg |
| 100 mg + 2 mL |
50 mg/mL |
2 units (0.02 mL) |
4 units |
6 units |
| 100 mg + 3 mL |
33.3 mg/mL |
3 units |
6 units |
9 units |
| 50 mg + 2 mL |
25 mg/mL |
4 units |
8 units |
12 units |
| 100 mg + 5 mL |
20 mg/mL |
5 units |
10 units |
15 units |
| 50 mg + 3 mL |
16.7 mg/mL |
6 units |
12 units |
18 units |
| 50 mg + 5 mL |
10 mg/mL |
10 units (0.10 mL) |
20 units (0.20 mL) |
30 units |
Two things follow. First, the PeRx figure checks out: 20 units at 10 mg/mL is 2 mg. Second, at the concentrated end the amounts sit at 2 to 6 units, where a 100-unit barrel's marks are hard to read accurately; how the barrels read is on insulin syringe units, and the GHK-Cu vial arithmetic works any vial and volume. The mixing figures for both vial sizes are on GHK-Cu reconstitution. In a GLOW or KLOW blend, GHK-Cu is one of three or four components and each draw carries a fixed share of it; that arithmetic is on GLOW vs KLOW.
Status that bears on the injection
GHK-Cu is not among the seven peptide substances the FDA's Pharmacy Compounding Advisory Committee scheduled for its July 2026 meeting (Federal Register document 2026-07361, 2026-04-16, read 2026-10-27). FDA's own page on bulk substances that may present significant safety risks could not be retrieved by this site's automated reader on 2026-10-27, so its current entry for GHK-Cu is not reported here.
What is not established
No label and no regulator's statement of a site, route or schedule. No human trial or case series of subcutaneous GHK-Cu. No measurement of the sting, of absorption from different sites, or of how long injected GHK-Cu stays in the blood of a person. No study behind the vitamin C rule. Medibact's GHK-Cu guide covers the compound. Decisions about whether and how to use it belong with a clinician.
Sources and dates
Opened 2026-10-27: ClinicalTrials.gov v2 API search for GHK-Cu (4 records: NCT07437586, NCT07706361, NCT07888595, NCT05932732); PubMed through NCBI E-utilities for GHK-Cu with injection or subcutaneous and the human tag (2), for GHK with ascorbic acid or vitamin C (8), and the abstracts of PMIDs 41476424 and 25731775; Federal Register document 2026-07361; the PeRx page "Where to Inject GHK-Cu" (updated 2026-08-29), the Range Medical GHK-Cu injection guide and the copperpeptidedirect.com injection-sites page; Google's US results for "where to inject ghk cu" via DataForSEO. From this site's GHK-Cu dosage page with its read dates (2026-09-18): the vendor figures, the DailyMed searches and the Kapoor and Miller studies. Pages on unrelated domains that rank for this search were not used as sources. Unit arithmetic by this site. Corrections go to the contact page.
